Greg Verdine’s LifeMine eyes the clinic next year with T-cell immunosuppressive and antifungal: #JPM24

SAN FRAN­CIS­CO — LifeM­ine Ther­a­peu­tics, a biotech in­formed by the long his­to­ry of fun­gi, ex­pects to en­ter the clin­ic ear­ly next year with a T-cell im­muno­sup­pres­sive and with an an­ti­fun­gal about six months lat­er, CEO Greg Ver­dine told End­points News.

“I’m say­ing it for the first time that these are the two ar­eas right now that we’re fo­cus­ing in,” Ver­dine said in an in­ter­view on the side­lines of the an­nu­al JP Mor­gan Health­care Con­fer­ence in the Bay Area. The biotech is al­so work­ing on on­col­o­gy pro­grams and else­where, he not­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.